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Research Highlights 
• In a population-based cohort of 235 patients diagnosed with oropharyngeal cancer, 60% of 
patients were positive for HRHPV.  
• After adjustment, patients with HPV positive OPC had 89% reduction in risk of death (HR = 
0.11, 95% CI 0.05-0.25), and an 85% reduction in risk of disease progression (HR = 0.15 95% 
CI 0.07-0.30).  
• The prevalence of HPV 16 in OPC indicates the potentially significant impact of 
prophylactic immunisation on this increasingly incident disease. 
 
Abstract 
Oropharyngeal cancer (OPC) is increasing on a global scale, including the component driven by 
high-risk human papillomavirus (HR-HPV); contemporary data that provide insight into the 
prognosis of this disease in addition to the fraction attributable to HR-HPV are essential to inform 
primary and secondary disease management strategies. A population-based cohort of 235 
patients diagnosed with OPC between 2013-15 in Scotland was assessed for HPV status using 
molecular genotyping. Associations between HR-HPV status and key clinical and demographic 
variables were estimated using the Pearson chi-squared test. Rates of overall survival (OS) and 
progression-free survival (PFS) were estimated and visualized using Kaplan–Meier curves. HPV DNA 
(largely HPV 16) was identified in 60% of cases. After adjustment for age, gender, deprivation, 
smoking, alcohol consumption and tumour stage, patients with HR-HPV positive OPC had 89% 
reduction in risk of death (HR = 0.11, 95% CI 0.05-0.25), and an 85% reduction in risk of disease 
progression (HR = 0.15 95% CI 0.07-0.30). HPV positivity was not associated with age, deprivation or 
smoking status, whereas those who reported excess alcohol consumption were less likely to be HPV 
positive. The prevalence of HPV-associated OPC is high in Scotland and strongly associated with 
dramatically improved clinical outcomes including survival. Demographic/behavioural variables 
did not reliably predict HPV positivity in this cohort which underlines the importance of 
laboratory confirmation. Finally, the dominance of HPV 16 in OPC indicates the significant impact 
of prophylactic immunisation on this disease.   
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Introduction 
Oropharyngeal cancer (OPC) is increasing globally and the rate has doubled in the past 15 years in 
the United Kingdom with clinicians describing it as an ‘epidemic’ [1-3]. In Scotland, OPC is one of the 
most increasingly incident cancers – especially among men [4]. Tobacco use and alcohol 
consumption remain the major risk factors for head and neck cancers however, an increase in high-
risk human papillomavirus (HR-HPV) driven OPC has also been observed [5,6].  Analyses of Scottish 
Cancer Registry head and neck cancer incidence trends over the past 40 years show that the rate of 
laryngeal cancer, which is strongly associated with tobacco consumption, has remained essentially 
stable. Oral cancer, which is associated with alcohol consumption, is steadily increasing, while OPC 
has risen comparatively more rapidly with a rate that has increased nearly 3-fold in recent years and 
is projected to rise further[7]. In relation to risk factors in head and neck cancer in Scotland these 
trends indicate a continued role of tobacco, an increasing role of alcohol, and a dramatic and 
relatively new role of the HPV [8].  
 
The fraction of OPC associated with HPV varies significantly with geographic location; in the US 
prevalence is around 60% whereas in South America the attributable fraction is less than 5% [9].  A 
study of approximately 1500 archived OPC cases from 11 participating centres in the UK [10] 
(diagnosed between 2002 and 2011) showed approximately 50% were HR-HPV DNA-positive, largely 
for HPV type 16.  Furthermore, the main HPV genotype identified in oral rinse samples from the 
general Scottish population was HPV 16 [11]. HPV is thought to be acquired through sexual exposure 
[12,13] although the natural history of HPV-associated OPC is not as well defined as other HPV-
associated neoplasms such as cervix.    Although the increase in OPC incidence is of clear concern, 
patients with HPV-driven OPC generally have a better prognosis compared to those patients who are 
HPV-negative [14]. Of note, the International Collaboration on Oropharyngeal Cancer Network for 
Staging (ICON-S) has developed a new staging classification system informed by HPV-status which 
recognises the improved clinical outcomes; and this has now been incorporated into the 8th edition 
TNM classification [14]. 
Studies of North American populations suggest that the sociodemographic status of head and neck 
cancer patients may also be changing, with an increasing proportion of patients with OPC diagnosis 
being younger and more socioeconomically affluent [15]. This phenomenon is not mirrored in 
Scotland, since recent national cancer registry data show that patients from the most deprived areas 
consistently had the highest rates of OPC [8]. While the HPV status of OPCs is not available in 
Scottish cancer registry data, the association between deprivation and cancer rates may reflect the 
overwhelming influence of tobacco and alcohol consumption in head and neck cancer oncogenesis 
in Scotland. The Scottish population has historically had a high rate of smoking, with 45% of adults 
reporting as current or ex-regular cigarette smokers (as of 2016), with about 60% residing in the 
most deprived areas [16]. Excessive alcohol consumption in Scotland is also high with one in four 
adults consuming harmful levels in 2016 [16].  
 
Prior to 2013, HPV testing of OPC in Scotland was performed opportunistically at the treating 
clinician’s request, thereafter it was offered as a service to all Scottish health boards via the National 
reference laboratory facility. This evaluation is one of the first to assess outcomes in a prospective, 
population based cohort of OPC patients, where HPV genotyping has been performed by a 
standardised methodology in a centralised location. We present data on the prevalence of HPV in 
OPC in Scotland and the association with key social variables and clinical indicators/outcomes. 
Furthermore, we investigate whether improved outcome associated with HPV-driven OPC is 
reflected in populations where rates of tobacco use and alcohol are particularly high, such as the 
West of Scotland.   
 
Materials and Methods 
Dimension and characteristics of patient cohort  
All OPCs, including sub-sites of the tonsil, base of tongue, soft palate, and pharyngeal walls 
diagnosed in the West of Scotland Cancer Network between April 2013 and June 2015 underwent 
pathology review and prospective HPV genotyping as part of routine clinical care. The Health Boards 
included in the present analysis covered the following locations: West Dunbartonshire; East 
Dunbartonshire; East Renfrewshire; Glasgow City; Inverclyde, Renfrewshire, Forth Valley, 
Lanarkshire, Ayrshire and Arran which cover a population of approximately 2.5 million people.  All 
individuals accessing health care in Scotland are assigned a unique 10-digit number, which allows 
linkage of clinical, social and laboratory data.  Sociodemographic and clinical data were extracted 
from the West of Scotland Cancer Network Head and Neck Cancer Quality Performance Indicators, 
which are collected by all health boards in Scotland and used to drive quality improvement in cancer 
care across NHS Scotland and clinical records.  The variables collected were: Date of diagnosis - 
taken as date of initial diagnostic biopsy sample collection, age at diagnosis, cancer stage; 7th edition 
TNM classification (TNM),  8th edition TNM classification for HPV positive OPCs/International 
Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S) [14] which takes into account 
HPV status, treatment modality,  date of relapse if occurred  and if applicable date and cause of 
death, smoking status (never v. ever) at time of diagnosis and self-reported alcohol excess. Alcohol 
excess is defined by NHS Scotland as consuming alcohol at >=21 units or more per week for men and 
>=14 units per week for women] or documentation of “heavy”, “excessive” or “dependency” on 
alcohol within clinical records). In addition, area-based socioeconomic status was obtained - via the 
Scottish Index of Multiple Deprivation (SIMD) where 1 and 5 are the most and least deprived 
respectively.    Data were extracted by treating clinicians and all patient identifiable data were 
removed prior to statistical analysis. Study governance and ethical considerations were through NHS 
Greater Glasgow and Clyde Research and Development Office, the Clinical Effectiveness Team and a 
data sharing agreement with the West of Scotland Cancer Network, NHS. Data was censored at 
November 2016   
 
Nucleic acid extraction & HPV genotyping 
 
Formalin fixed, paraffin-embedded (FFPE) block was selected and a 10 μm section obtained for 
nucleic acid extraction. Nucleic acid extraction was performed using reagents within the DNA mini 
kit (Qiagen, Hilde Germany) with an adaptation to the protocol to maximise recovery of HPV DNA 
[17].  Subsequently, HPV genotyping was performed using the PCR and luminex based Optiplex HPV 
Genotyping test (Diamex, Heidelberg, Germany). This assay detects 24 HPV types including all 
established HR types and, as a check for specimen adequacy, incorporates a cellular housekeeping 
control (betaglobin). This assay was used for the recent UK prevalence study of 1500 OPC referred to 
earlier [10] Agreement of the this assay with p16INK4a immunohistochemistry has been shown to be 
90% in oropharyngeal samples with no significant difference in the distribution of discordant results 
between the two tests. Furthermore, positivity according to this assay has been shown to correlate 
with cause-specific survival in Scottish cohorts as reported in Wells et al (2015) [10, 18]. All testing 
was performed at a centralised reference laboratory.  
 
Analysis of HPV status with clinical outcomes 
Associations between HR-HPV status and clinical and demographic variables were estimated using 
the Pearson chi-squared test. Both unadjusted and adjusted odds ratios (ORs) for HPV positivity and 
95% confidence intervals (CIs) were calculated using logistic regression. Linear trend test was 
performed to investigate whether there was an increasing trend in the risk of HPV positive OPC with 
increasing age. Rates of overall survival (OS) and progression-free survival (PFS) were determined 
and univariate comparisons visualized using Kaplan–Meier curves.  The univariate impact of each 
variable on survival was measured using Cox proportional-hazards regression. An adjusted model 
was created to obtain the adjusted hazard ratios for HR-HPV status with adjustment of the following 
covariates: gender, age at diagnosis (<50, 50-59, 60-69, 70-79 and 80+), SIMD, smoking and alcohol 
status and TNM classification 7 of cancer. Subset analysis on the HPV+ patients were carried out to 
obtain univariate and adjusted hazard ratio for ICON stage. 
All statistical analysis was carried out using R version 3.2.3. All variables with P-values <0.05 were 
considered to be statistically significant. 
Results 
Description of cohort 
A total of 235 patients were diagnosed with OPC between April 2013 and June 2015. Technically 
valid HPV results were obtained for 229 patients with 6 excluded due to non- amplification of the 
cellular housekeeping gene. Only 22 % of the 229 OPC patients were female and the median age was 
60 (IQR 54-69). Most of the cohort was resident in a deprived area (37.6% in SIMD1 and 21% in 
SIMD2). The majority reported having ever smoked tobacco (65%) with 31% reporting drinking 
alcohol to excess (Table 1).   
HPV positivity and association with extrinsic risk factors 
HPV DNA was identified in 60% of the cases (136/229). Single infections with 16, 18, 33, 35 were 
identified in 127, 2, 1, and 1 case, respectively. The occurrence of multiple infections of 16/6, 16/59, 
18/82, 6/16/33 and 18/59/82 all occurred in a single case each. All bar one of the HPV positive cases 
included at least 1 established HR-HPV type. 
 
Influence of gender and risk factors are summarised in Table 1. Men were twice as likely as women 
to have an HPV positive tumour (OR 2.44, 95% CI 1.18-5.05, P=0.02). Those who reported drinking 
alcohol to excess were 70% less likely to be HPV positive (OR 0.30, 95% CI 0.14-0.63, P=0.001). HPV 
positivity was not associated with social deprivation as measured by SIMD (P = 0.2) or age (linear 
trend P = 0.7), or smoking status (P = 0.1). 
HPV status and survival  
A total of 35 patients were excluded from the survival analysis: one was lost to follow-up and 34 
received treatment intent of best support palliative care due to frailty and were unable to tolerate 
treatment. Post-exclusions, the median follow-up time of the remaining cohort after OPC diagnosis 
was 2.2 years (range from 19 days to 3.4 years). In total, 23% patients (45/194) died and 28% 
patients (55/194) had disease progression during the follow-up period.  One-year OS rate for HPV 
negative patients was 75.7% while for HPV positive patients OS was 95.2%. One-year PFS rate for 
HPV negative and HPV positive patients was 67.1% and 92.7%, respectively (Figures 1 and 2). One-
year OS rates for the patients who smoked was 86.4% compared with 90.2% for the patients who 
reported never smoking. One-year OS rate for the patients who drank alcohol to excess was 80.4% 
compared with 91.5% for those who did not.  In our data we observed an increase in the point 
estimates for death and disease free survival as TNM classification 7 increased from stage 1 to 4, but 
use of ICON stage for the HPV positive population was not discriminatory.  
 
Univariate analysis also showed that HPV negative status and alcohol consumption were significantly 
associated with increased risk of death (both P<0.001, Table 2). After adjustment for age, gender, 
SIMD, smoking and drinking status and tumour stage, patients with HR-HPV positive OPC had 89% 
reduction in risk of death (HR = 0.11, 95% CI 0.05-0.24, P<0.001, Table 2), and had 84% reduction in 
risk of disease progression (HR = 0.15, 95% CI 0.07-0.30, P<0.001, Table 3) compared with those with 
HPV negative OPC. The risk of death increased with age in the fully adjusted model. Patients who 
reported drinking alcohol to excess had 2.3 times the risk of death (HR OS = 2.33, 95% CI 1.06-5.18, 
P=0.04) compared with those who did not drink alcohol to excess.  
 
Discussion 
We have conducted a detailed population-based evaluation to examine the impact of demographic, 
behavioural, and viral factors associated with OPC in a context where both disease prevalence and 
non-viral risk factors (alcohol consumption and smoking) are high.  We have demonstrated that HR-
HPV prevalence among OPCs in the West of Scotland was 60% and that HR-HPV positivity was higher 
in males compared to females, and lower amongst those who reported drinking alcohol to excess. 
We also confirmed that in our population HR-HPV status was strongly associated with improved 
overall and progression-free survival. It was of interest that individuals reporting tobacco exposure 
were as likely to have cancers associated with HR-HPV as those individuals who reported no history 
of tobacco use - a finding at variance with other previously reported UK data [19]. 
Studies suggest that incidence of HR-HPV detection in OPCs varies widely depending on geographic 
location and period of time.  We report HR-HPV rates of 49% among women and 62.4% among men, 
with an overall positivity of 60%. This is broadly in line with the UK based results of Schache et al [3] 
and reflects a more recent period of assessment.  Beyond the UK, studies of HR-HPV prevalence in 
OPCs in the most recent decade reports range from 6.1% in Spain [20], 38% in the Netherlands [21] 
and 62% in Denmark [22]. US estimates are consistently higher at around 60-70% [9]. A confounder 
to cross-study comparison is the different methods by which HPV positive status is defined, which 
vary across studies and include nucleic acid amplification tests, immunohistochemistry with 
p16INK4a,  in-situ hybridisation and combinations thereof.  In this work we used a sensitive PCR-
based assay to confirm HPV status rather than p16INK4a; this assay has been shown to have a high 
level of agreement (90%) with p16INK4a immunohistochemistry, with no difference in the 
distribution of discordant results in OPC cases. Furthermore, HPV status determined by this assay 
has been shown to be independently associated with disease specific survival as indicated in 
previous studies, national audit and the data outlined in the present manuscript [10,18]. Thus, 
although testing with multiple markers/chemistries for HPV status provides further validation, we 
are confident that the assay is a robust and credible marker of HPV status. Additionally, the 
advantage of this approach is that it also provides information on type specific prevalence to allow 
the monitoring of epidemiological trends.   
 
Country-specific data on the attributable fraction of HPV-associated disease are important as they 
will inform the decisions surrounding the utility and cost effectiveness of HPV vaccination including 
gender neutral vaccination.  Certainly, significant impact of the vaccine on HR-HPV prevalence and 
disease outcomes including high grade cervical intraepithelial neoplasia (CIN2+) has already been 
observed in young women attending for screening in Scotland [23,24].  As reports suggest that HPV 
vaccination induces HPV antibodies in the oral cavity it is reasonable to assume that the vaccine will 
ultimately have an impact on OPC incidence [25,26].   This may be realised more rapidly in a gender 
neutral programme given that we and others have shown a significantly higher prevalence of OPCs  
associated with HPV in men compared to women [9]. 
We report an inverse association between HPV positivity and excess alcohol consumption.  No other 
factor including social deprivation or cancer stage was associated with viral status.   This is an 
interesting and important observation as it indicates that in Scotland, patient-related demographic 
and clinical factors cannot be reliably used to predict the HPV status of patients OPCs. Furthermore, 
we did not observe an inverse relationship between HPV positivity and smoking status unlike other 
studies [9] and this may have been affected by the high smoking rates and the socio-economic status 
of our study population (Table 1).  
In our data TNM classification 7 was more predictive of outcome than the new staging system that 
takes into account HPV status, although numbers were small. The British Association of Head and 
Neck Oncologists (BAHNO) have raised concerns of the use of TNM 8 and have suggested TNM 7 
continues to be recorded.  While the new staging system reflects improved understanding of cancer 
biology and clinical outcome of HPV-positive OPCs, further research is required to define if TNM 8 is 
generalisable to all populations and can be used to change treatment decisions.  
In the adjusted analysis HPV status was strongly associated with improvement in overall and 
progression free survival during a median of 2-years follow up. For individuals whose disease recurs, 
the median time to progression was similar for HPV positive and HPV negative OPCs, with most 
people experiencing disease progression in the first year after completion of therapy [27]. The 
improvement in survival associated with HPV positive disease is in accordance with other studies of 
OPC; D’Souza et al (2016) recently reported a 66% reduction in the hazard of death among HPV 
positive OPC compared to HPV negative cases [28] and in other HPV-associated cancers [29,30].  It 
has been hypothesised that improved prognosis in HPV positive cancers may be due to better 
response rates to treatment through increased sensitivity to radiation and host immune response to 
the tumour [31].  While treatment for HPV positive and negative OPCs remains the same in many 
settings, the results of de-intensifying treatment trials in HPV positive OPC will be informative for 
future evidence-based management strategies [32]. The reduction in survival with increasing age and 
heavy alcohol consumption has implications for the ability to deliver and tolerate curative 
treatment, which may impact survival. Cause of death was out with the scope of the present study 
but nutritional factors and co-morbidities in these patient groups should be further evaluated.  
Conclusion 
In this evaluation of OPC patients in whom the prevalence of traditional risk factors of drinking and 
smoking was high; 60% of tumours were HPV positive with positivity dominated by HPV type 16. 
While we confirmed that in our population HR-HPV status was strongly associated with improved 
overall and progression-free survival, HPV status could not be reliably predicted by 
demographic/clinical characteristics alone emphasising the need for laboratory confirmation. While 
primary prevention of most OPCs through vaccination is likely to exert a significant influence on the 
burden of this disease in time, in the shorter term, Scotland must address other interventions to 
promote healthy living in order to reduce excessive alcohol consumption and smoking. Such 
interventions if successfully implemented, would have far-reaching benefits beyond the reduction of 
OPC.  
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Variable Level Number (N = 229)* HR-HPV pos (N= 136)  Unadjusted  Adjusted (full model)** 
    n % n % OR 95% CI lower 95% CI upper p values OR 95% CI lower 95% CI upper p values 
Sex Female 51 22.3 25 49.0 1       1       
  Male 178 77.7 111 62.4 1.72 0.92 3.23 0.09 2.44 1.18 5.05 0.02 
Age <50 27 11.8 20 74.1 1 
  
    
  
  
  50-59 86 37.6 58 67.4 0.73 0.27 1.92 0.5   
  
  
  60-69 60 26.2 30 50.0 0.35 0.13 0.95 0.04   
  
  
  70-79 49 21.4 25 51.0 0.36 0.13 1.02 0.05   
  
  
  80 and over 7 3.1 3 42.9 0.26 0.05 1.48 0.1   
  
  
  Age in years (19-91) 229   
 
  0.97 0.95 1 0.04 (trend) 0.99 0.97 1.02 0.7 (trend) 
SIMD 1: most deprived 86 37.6 44 51.2 1 
  
  1 
  
  
  2 48 21.0 27 56.3 1.23 0.6 2.5 0.6 1.01 0.44 2.33 1.0 
  3 35 15.3 26 74.3 2.76 1.16 6.57 0.02 4.24 1.45 12.35 0.01 
  4 29 12.7 20 69.0 2.12 0.87 5.18 0.1 1.75 0.64 4.75 0.3 
  5: least deprived 19 8.3 13 68.4 2.07 0.72 5.94 0.2 1.39 0.4 4.86 0.6 
  Missing 12 5.2 6 50.0   
  
  0.94 0.18 5 0.9 
Smoking status No  63 27.5 50 79.4 1 
  
  1 
  
  
  Yes 149 65.1 77 51.7 0.28 0.14 0.55 0.0003 0.52 0.23 1.17 0.1 
  Missing 17 7.4 9 52.9   
  
  1.12 0.18 6.94 0.9 
Alcohol status No  129 56.3 91 70.5 1 
  
  1 
  
  
  Yes 71 31.0 30 42.3 0.31 0.17 0.56 0.0001 0.3 0.14 0.63 0.001 
  Missing 29 12.7 15 51.7   
  
  0.45 0.12 1.69 0.2 
Smoking & 
Alcohol 
No/either 138 60.3 98 72.1 1        
 Both 66 28.8 27 19.8 0.28 0.15 0.52 0.00005     
 Missing 25 10.9 11 8.1         
TNM stage 1 13 5.7 2 15.4 1 
  
  1 
  
  
  2 26 11.4 11 42.3 4.03 0.74 21.98 0.1 10.94 1.6 74.91 0.01 
  3 20 8.7 13 65.0 10.21 1.75 59.65 0.01 23.37 3.09 176.86 0.002 
  4a 148 64.6 100 67.6 11.46 2.44 53.74 0.002 23.8 3.99 141.98 0.001 
  4b 12 5.2 6 50.0 5.5 0.84 36.2 0.08 17.65 1.94 160.87 0.01 
  4c 4 1.7 2 50.0 5.5 0.46 65.16 0.2 8.38 0.63 112.14 0.1 
  Missing 6 2.6 2 33.3   
  
  5.81 0.39 86.24 0.2 
 
*Valid HPV results available for 229/235 cases 
**An Adjusted for all variables in the table with the exception of treatment.  It is highly associated with TNM stage therefore not included in the adjusted model to avoid collinearity. 
Table 1 Factors associated with high-risk human papillomavirus (HR-HPV) among OPC cases 
 
 
  
Variable Level Number 
(N = 
194)* 
Number 
with all 
cause 
death 
Person 
years 
follow 
up 
Rate 
per 100 
person 
years 
95% CI 
Lower  
95% 
CI 
Upper  
Univariate 
HR 
Lower 
95% CI 
Upper 
95% CI 
p value Adjusted 
(full) 
HR**  
Lower 
95% CI 
Upper 
95% CI 
p value 
HR-HPV status Negative 70 31 132.7 23.4 15.9 33.1 1.00       1.00       
  Positive 124 14 269.8 5.2 2.8 8.7 0.20 0.11 0.39 <0.00001 0.11 0.05 0.24 <0.00001 
Sex Female 39 7 80.8 8.7 3.5 17.9 1.00 
  
  1.00 
  
  
  Male 155 38 321.8 11.8 8.4 16.2 1.33 0.59 2.99 0.5 1.04 0.44 2.69 0.9 
Age <50 25 1 60.3 1.7 0.04 9.2 1.00 
  
  1.00 
  
  
  50-59 79 13 172.2 7.5 4.0 12.9 4.45 0.58 34.04 0.2 1.55 0.34 14.88 0.6 
  60-69 50 12 98.5 12.2 6.3 21.3 7.25 0.94 55.82 0.06 1.92 0.40 18.93 0.5 
  70-79 38 18 69.6 25.9 15.3 40.9 14.59 1.94 109.70 0.01 10.39 2.42 97.07 0.0007 
  80 and over 2 1 2.0 48.9 1.2 272.6 28.87 1.80 463.90 0.02 104.44 6.53 1744.56 0.003 
SIMD 1: most deprived 68 20 132.0 15.1 9.3 23.4 1.00 
  
  1.00 
  
  
  2 37 6 78.4 7.7 2.8 16.7 0.51 0.20 1.26 0.1 0.66 0.21 1.81 0.4 
  3 33 7 70.0 10.0 4.0 20.6 0.57 0.23 1.42 0.2 1.30 0.47 3.25 0.6 
  4 27 9 53.1 17.0 7.8 32.2 1.11 0.51 2.45 0.8 2.77 1.09 6.70 0.03 
  5: least deprived 18 3 38.6 7.8 1.6 22.7 0.51 0.15 1.73 0.3 0.91 0.23 2.70 0.9 
  Missing 11 0 30.4 0.0 0.0 12.1   
  
  0.11 0.00 1.18 0.07 
Smoking status No  61 10 129.0 7.8 3.7 14.3 1.00 
  
  1.00 
  
  
  Yes 118 34 235.7 14.4 10.0 20.2 2.06 0.99 4.30 0.05 1.64 0.64 4.45 0.3 
  Missing 15 1 37.9 2.6 0.1 14.7   
  
  4.23 0.28 48.34 0.3 
Alcohol status No  118 18 256.9 7.0 4.2 11.1 1.00 
  
  1.00 
  
  
  Yes 51 24 84.7 28.3 18.1 42.1 4.34 2.32 8.12 <0.00001 2.32 1.06 5.18 0.04 
  Missing 25 3 61.0 4.9 1.0 14.4   
  
  0.69 0.12 2.82 0.6 
TNM stage 1 13 2 27.6 7.2 0.9 26.2 1.00 
  
  1.00 
  
  
  2 23 10 41.2 24.3 11.6 44.7 3.20 0.70 14.64 0.1 3.20 0.86 17.30 0.08 
  3 20 2 45.5 4.4 0.5 15.9 0.60 0.09 4.29 0.6 3.85 0.53 28.22 0.2 
  4a-c*** 133 31 273.5 11.3 7.7 16.1 1.50 0.36 6.26 0.6 9.97 2.57 56.41 0.0005 
  Missing 5 0 14.8 0.0 0.0 24.9   
  
    
  
  
ICON 
stage***** 
1 16 3 34.3 8.7 1.8 25.6 1.00 
  
    
  
  
  2 71 4 156.8 2.6 0.7 6.5 0.30 0.07 1.34 0.1   
  
  
  3-4**** 36 7 75.7 9.2 3.7 19.0 0.97 0.24 3.87 1.0   
  
  
  Missing 1 0 3.0 0.0 0.0 122.9   
  
    
  
  
 
* individual removed from OS analysis as lost follow up (no date of death and no date of alive); individuals also removed from OS analysis as treatment = BSC 
**An Adjusted for all variables in the table with the exception of ICON stage.  They are highly associated with TNM stage therefore not included in the adjusted model to avoid collinearity. 
***For TNM stage, 4a-c combines the levels 4a (126 cases, 30 died), 4b (6 cases, 1 died) and 4c (1 case, 0 died). 
****For ICON stage, 3-4 combines the levels 3 (35 cases, 7 died) and 4 (1 case, 0 died). 
*****Only select HRHPV+ cases N=124 
 
Table 2 Hazard ratios for OS 
 
 
 
 
  
Variable Level Number 
(N = 194) 
Number 
recur or 
die 
Person 
years 
follow 
up 
Rate 
per 100 
person 
years 
95% CI 
Lower  
95% CI 
Upper  
Univariate 
HR 
Lower 
95% CI 
Upper 
95% CI 
p value Adjusted 
(full) 
HR* 
Lower 
95% CI 
Upper 
95% CI 
p value 
HR-HPV status Negative 70 35 129.6 27.0 18.8 37.6 1.00       1.00       
  Positive 124 20 263.2 7.6 4.6 11.7 0.27 0.16 0.48 <0.00001 0.15 0.07 0.30 <0.00001 
Sex Female 39 9 79.8 11.3 5.2 21.4 1.00 
   
1.00 
  
  
  Male 155 46 313.0 14.7 10.8 19.6 1.30 0.64 2.66 0.5 0.98 0.47 2.24 1.0 
Age <50 25 2 60.1 3.3 0.4 12.0 1.00 
   
1.00 
  
  
  50-59 79 17 168.1 10.1 5.9 16.2 3.12 0.72 13.54 0.1 1.46 0.41 7.79 0.6 
  60-69 50 14 97.9 14.3 7.8 24.0 4.37 0.99 19.25 0.051 1.59 0.42 8.71 0.5 
  70-79 38 21 64.6 32.5 20.1 49.7 9.55 2.23 40.91 0.002 8.65 2.57 44.83 0.0002 
  80 and over 2 1 2.0 48.9 1.2 272.6 15.93 1.43 176.98 0.02 45.72 3.49 454.44 0.007 
SIMD 1: most deprived 68 23 129.0 17.8 11.3 26.8 1.00 
   
1.00 
  
  
  2 37 9 76.7 11.7 5.4 22.3 0.65 0.30 1.41 0.3 1.06 0.42 2.49 0.9 
  3 33 9 67.1 13.4 6.1 25.5 0.67 0.30 1.49 0.3 1.35 0.55 3.05 0.5 
  4 27 9 52.1 17.3 7.9 32.8 0.95 0.44 2.05 0.9 2.10 0.85 4.88 0.1 
  5: least deprived 18 5 37.5 13.3 4.3 31.1 0.76 0.29 2.00 0.6 1.34 0.45 3.39 0.6 
  Missing 11 0 30.4 0.0 0.0 12.1   
   
0.05 0.00 0.49 0.01 
Smoking status No  61 12 125.4 9.6 4.9 16.7 1.00 
   
1.00 
  
  
  Yes 118 41 231.3 17.7 12.7 24.0 2.00 1.03 3.90 0.04 1.70 0.73 4.12 0.2 
  Missing 15 2 36.0 5.5 0.7 20.0   
   
11.43 1.30 95.61 0.0003 
Alcohol status No  118 23 250.9 9.2 5.8 13.8 1.00 
   
1.00 
  
  
  Yes 51 27 82.3 32.8 21.6 47.7 3.84 2.17 6.79 <0.00001 2.08 0.99 4.33 0.1 
  Missing 25 5 59.5 8.4 2.7 19.6   
   
0.66 0.13 2.39 1.0 
TNM stage 1 13 2 27.1 7.4 0.9 26.7 1.00 
   
1.00 
  
  
  2 23 13 37.9 34.3 18.3 58.7 4.58 1.03 20.37 0.05 4.55 1.25 24.56 0.02 
  3 20 4 44.8 8.9 2.4 22.9 1.20 0.22 6.53 0.8 4.69 0.94 29.13 0.06 
  4a-c** 133 36 268.2 13.4 9.4 18.6 1.72 0.41 7.16 0.5 9.26 2.41 52.15 0.001 
  Missing 5 0 14.8 0.0 0.0 24.9   
   
0.61 0.00 12.65 0.8 
ICON stage**** 1 16 4 32.0 12.5 3.4 32.1 1.00 
   
  
  
  
  2 71 7 155.1 4.5 1.8 9.3 0.37 0.11 1.26 0.1   
  
  
  3-4*** 36 9 73.1 12.3 5.6 23.4 0.92 0.28 3.07 0.9   
  
  
  Missing 1 0 3.0 0.0 0.0 122.9   
   
  
  
  
 
*An Adjusted for all variables in the table with the exception of ICON stage.  They are highly associated with TNM stage therefore not included in the adjusted model to avoid collinearity. 
**For TNM stage, 4a-c combines the levels 4a (126 cases, 34 died/recur), 4b (6 cases, 2 died/recur) and 4c (1 case, 0 died/recur). 
***For ICON stage, 3-4 combines the levels 3 (35 cases, 9 died/recur) and 4 (1 case, 0 died/recur). 
*****Only select HRHPV+ cases N=124 
Table 3 Hazard ratios for PFS 
 
 
 
 
 
  
     OS  PFS 
Variable Level HR Lower 95% 
CI 
Upper 95% 
CI 
p value HR Lower 95% 
CI 
Upper 95% 
CI 
p value 
Sex Female 1.00 
  
  1.00 
  
  
  Male 0.55 0.11 3.36 0.48 0.53 0.14 2.34 0.378 
Age <50 1.00 
  
  1.00 
  
  
  50-59 3.66 0.29 529.78 0.36 4.95 0.52 667.62 0.196 
  60-69 8.56 0.58 1313.37 0.13 8.31 0.65 1199.88 0.113 
  70-79 18.45 1.62 2678.93 0.01 21.83 2.27 2974.37 0.004 
  80 and over 160.13 0.53 58517.87 0.07 53.83 0.23 12923.17 0.119 
SIMD 1: most deprived 1.00 
  
  1.00 
  
  
  2 1.99 0.16 17.15 0.55 3.65 0.66 21.41 0.135 
  3 3.86 0.89 20.02 0.07 4.57 1.23 20.60 0.023 
  4 3.99 0.77 22.28 0.10 3.97 0.77 21.01 0.096 
  5: least deprived 1.45 0.01 21.12 0.82 3.77 0.32 29.32 0.252 
Smoking status No  1.00 
  
  1.00 
  
  
  Yes 1.95 0.38 13.20 0.43 1.54 0.42 6.37 0.518 
Alcohol status No  1.00 
  
  1.00 
  
  
  Yes 5.30 1.28 28.40 0.02 5.19 1.49 20.62 0.009 
ICON stage 1 1.00 
  
  1.00 
  
  
  2 0.78 0.14 4.81 0.78 0.91 0.23 4.10 0.897 
  3-4 2.88 0.68 15.18 0.15 1.92 0.52 8.07 0.329 
 
Table A1 Adjusted hazard ratios for ICON for HRHPV+ patients only (N=124) 
 
 
 
 
 
 
 
